Universal Health Services, Inc. (UHS) Key Metrics
UHS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.91B
- Enterprise value
- $15.69B
- P/E (TTM)
- 7.6 10-yr median 14.3
- Forward P/E
- 7.3
- PEG ratio
- 1.21
- Price / sales
- 0.6 10-yr median 0.9
- Price / book
- 1.4 10-yr median 1.9
- EV / EBITDA
- 5.6 10-yr median 8.7
- Dividend yield
- 0.38% $0.80 a year
- Beta
- 1.03
UHS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsUHS valuation Price multiples at each fiscal year-end price.
UHS returns How much profit the business earns on the capital it uses.
UHS per-share figures Results divided by the shares outstanding at year-end.
UHS financial health Debt, liquidity and how easily interest is covered.
UHS efficiency & capital use Working capital cycle and where the cash goes.
UHS valuation history
UHS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
UHS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
UHS cash returned to shareholders
UHS price vs earnings per share
UHS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $14.05B | $12.18B | $10.69B | $10.40B | $10.85B | $11.77B | $12.77B | $10.93B | $10.92B | $10.47B |
| Enterprise value | $19.42B | $17.01B | $15.94B | $15.57B | $15.30B | $14.74B | $17.02B | $14.82B | $14.88B | $14.57B |
| P/E ratio | 9.4 | 10.7 | 14.9 | 15.4 | 10.9 | 12.5 | 15.7 | 14.0 | 14.5 | 14.9 |
| Price / sales | 0.8 | 0.8 | 0.7 | 0.8 | 0.9 | 1.0 | 1.1 | 1.0 | 1.0 | 1.1 |
| Price / book | 1.9 | 1.8 | 1.7 | 1.8 | 1.8 | 1.9 | 2.3 | 2.0 | 2.2 | 2.3 |
| Price / free cash flow | 16.5 | 10.8 | 20.4 | 39.7 | 387.1 | 7.2 | 16.5 | 20.6 | 19.0 | 78.5 |
| Price / operating cash flow | 7.5 | 5.9 | 8.4 | 10.4 | 12.3 | 5.0 | 8.9 | 8.1 | 9.2 | 8.1 |
| EV / sales | 1.1 | 1.1 | 1.1 | 1.2 | 1.2 | 1.3 | 1.5 | 1.4 | 1.4 | 1.5 |
| EV / EBITDA | 7.1 | 7.5 | 9.3 | 9.9 | 8.0 | 7.9 | 9.9 | 9.1 | 8.7 | 8.7 |
| EV / free cash flow | 22.9 | 15.1 | 30.4 | 59.4 | 545.6 | 9.1 | 22.0 | 28.0 | 26.0 | 109.3 |
| Earnings yield | 10.6% | 9.4% | 6.7% | 6.5% | 9.1% | 8.0% | 6.4% | 7.1% | 6.9% | 6.7% |
| Free cash flow yield | 6.0% | 9.2% | 4.9% | 2.5% | 0.3% | 13.8% | 6.1% | 4.8% | 5.2% | 1.3% |
| Dividend yield | 0.4% | 0.4% | 0.5% | 0.6% | 0.6% | 0.1% | 0.4% | 0.3% | 0.3% | 0.4% |
| Shareholder yield (dividends + buybacks) | 7.3% | 5.9% | 5.6% | 8.6% | 11.9% | 1.9% | 6.4% | 4.0% | 3.7% | 3.7% |
| Share price at fiscal year-end | $218.02 | $179.42 | $152.44 | $140.89 | $129.66 | $137.50 | $143.46 | $116.56 | $113.35 | $106.38 |
| Per share | ||||||||||
| Revenue per share | $269.38 | $233.12 | $203.66 | $181.48 | $151.06 | $135.05 | $127.79 | $114.90 | $108.07 | $99.27 |
| Earnings per share | $23.10 | $16.82 | $10.24 | $9.15 | $11.85 | $11.03 | $9.15 | $8.32 | $7.81 | $7.14 |
| Operating cash flow per share | $28.92 | $30.45 | $18.08 | $13.49 | $10.56 | $27.58 | $16.16 | $14.30 | $12.28 | $13.10 |
| Free cash flow per share | $13.17 | $16.54 | $7.48 | $3.55 | $0.33 | $19.00 | $8.70 | $5.65 | $5.95 | $1.35 |
| Cash per share | $2.14 | $1.86 | $1.70 | $1.39 | $1.38 | $14.31 | $0.69 | $1.12 | $0.77 | $0.34 |
| Book value per share | $112.87 | $98.18 | $87.69 | $80.19 | $72.76 | $73.81 | $61.82 | $57.49 | $51.80 | $46.08 |
| Tangible book value per share | $49.79 | $39.13 | $30.51 | $26.18 | $24.45 | $27.48 | $17.42 | $16.27 | $9.80 | $5.30 |
| Dividends per share | $0.80 | $0.79 | $0.79 | $0.79 | $0.79 | $0.20 | $0.60 | $0.40 | $0.40 | $0.40 |
| Capex per share | $15.75 | $13.90 | $10.60 | $9.94 | $10.22 | $8.58 | $7.45 | $8.66 | $6.33 | $11.74 |
| Debt per share | $85.43 | $72.99 | $76.53 | $71.40 | $54.48 | $49.01 | $48.41 | $42.65 | $41.94 | $42.04 |
| Shares outstanding | 64.5M | 67.9M | 70.1M | 73.8M | 83.7M | 85.6M | 89.0M | 93.8M | 96.3M | 98.4M |
| Change in shares outstanding | −5.1% | −3.2% | −5.0% | −11.8% | −2.2% | −3.9% | −5.0% | −2.7% | −2.1% | −2.3% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 21.4% | 17.8% | 11.9% | 11.3% | 16.0% | 16.0% | 15.0% | 15.0% | 15.8% | 16.0% |
| Return on invested capital (ROIC) | 12.7% | 11.4% | 8.0% | 7.0% | 10.5% | 10.9% | 9.9% | 9.9% | 9.9% | 10.2% |
| Return on assets (ROA) | 9.8% | 8.0% | 5.2% | 5.1% | 7.5% | 7.5% | 7.1% | 7.1% | 7.1% | 7.0% |
| Return on tangible assets | 12.5% | 10.9% | 7.2% | 7.1% | 11.0% | 9.9% | 10.6% | 10.5% | 11.2% | 11.1% |
| Free cash flow margin | 4.9% | 7.1% | 3.7% | 2.0% | 0.2% | 14.1% | 6.8% | 4.9% | 5.5% | 1.4% |
| Income quality (OCF / net income) | 1.25 | 1.81 | 1.77 | 1.47 | 0.89 | 2.50 | 1.77 | 1.72 | 1.57 | 1.83 |
| Financial health | ||||||||||
| Total debt | $5.51B | $4.96B | $5.37B | $5.27B | $4.56B | $4.19B | $4.31B | $4.00B | $4.04B | $4.14B |
| Cash & short-term investments | $137.8M | $126.0M | $119.4M | $102.8M | $115.3M | $1.22B | $61.3M | $105.2M | $74.4M | $33.7M |
| Net debt | $5.37B | $4.83B | $5.25B | $5.17B | $4.44B | $2.97B | $4.25B | $3.89B | $3.97B | $4.10B |
| Debt / equity | 0.76 | 0.74 | 0.87 | 0.89 | 0.75 | 0.66 | 0.78 | 0.74 | 0.81 | 0.91 |
| Debt / assets | 0.35 | 0.34 | 0.38 | 0.39 | 0.35 | 0.31 | 0.37 | 0.35 | 0.38 | 0.40 |
| Net debt / EBITDA | 1.96 | 2.13 | 3.06 | 3.28 | 2.33 | 1.59 | 2.47 | 2.38 | 2.31 | 2.44 |
| Current ratio | 1.05 | 1.27 | 1.40 | 1.33 | 1.14 | 1.32 | 1.23 | 1.34 | 0.97 | 1.28 |
| Quick ratio | 0.98 | 1.17 | 1.29 | 1.21 | 1.04 | 1.25 | 1.12 | 1.24 | 0.90 | 1.18 |
| Interest coverage | 12.7 | 9.0 | 5.7 | 7.9 | 16.0 | 12.5 | 7.5 | 7.6 | 9.0 | 11.0 |
| Working capital | $168.3M | $605.9M | $798.0M | $622.9M | $279.4M | $800.8M | $352.5M | $489.1M | −$50.0M | $364.0M |
| Invested capital | $12.65B | $11.50B | $11.40B | $11.09B | $10.53B | $9.29B | $9.75B | $9.28B | $8.96B | $8.64B |
| Tangible asset value | $3.34B | $2.75B | $2.19B | $1.98B | $2.15B | $2.44B | $1.63B | $1.61B | $1.01B | $594.8M |
| Net current asset value | −$5.14B | −$4.89B | −$4.95B | −$4.99B | −$4.63B | −$3.79B | −$4.17B | −$3.86B | −$3.91B | −$4.03B |
| Graham number | $242.18 | $192.77 | $142.11 | $128.49 | $139.27 | $135.34 | $112.82 | $103.72 | $95.41 | $86.04 |
| Graham net-net per share | −$98.38 | −$85.97 | −$83.55 | −$78.54 | −$64.12 | −$52.04 | −$53.61 | −$47.83 | −$46.05 | −$46.09 |
| Capital allocation | ||||||||||
| Dividends paid | $51.3M | $53.3M | $55.5M | $58.4M | $65.9M | $17.3M | $53.0M | $37.3M | $38.2M | $38.9M |
| Share buybacks (net) | $968.0M | $670.8M | $547.4M | $832.9M | $1.22B | $206.7M | $770.5M | $397.4M | $364.4M | $353.4M |
| Dividend payout ratio | 3.4% | 4.7% | 7.7% | 8.7% | 6.6% | 1.8% | 6.5% | 4.8% | 5.1% | 5.5% |
| Dividends + buybacks / free cash flow | 120.0% | 64.5% | 114.9% | 340.2% | — | 13.8% | 106.3% | 82.2% | 70.2% | 294.4% |
| Capex / revenue | 5.8% | 6.0% | 5.2% | 5.5% | 6.8% | 6.4% | 5.8% | 7.5% | 5.9% | 11.8% |
| Capex / operating cash flow | 54.4% | 45.7% | 58.6% | 73.7% | 96.8% | 31.1% | 46.1% | 60.5% | 51.5% | 89.7% |
| Capex / depreciation | 1.64 | 1.61 | 1.31 | 1.26 | 1.60 | 1.44 | 1.35 | 1.79 | 1.36 | 2.77 |
| Stock-based compensation / revenue | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% | 0.5% | 0.5% |
| SG&A / revenue | 47.4% | 48.4% | 50.8% | 51.4% | 49.7% | 49.6% | 50.1% | 49.8% | 48.8% | 47.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 50.2 | 50.9 | 54.4 | 51.3 | 50.2 | 51.9 | 49.3 | 51.0 | 51.6 | 51.2 |
| Days of inventory on hand | 49.8 | 50.3 | 51.9 | 52.7 | 50.8 | 49.6 | 44.9 | 44.4 | 43.2 | 42.7 |
| Days payables outstanding | 152.0 | 143.2 | 148.9 | 160.4 | 157.2 | 144.2 | 130.2 | 138.6 | 145.6 | 142.6 |
| Cash conversion cycle (days) | -52.0 | -42.0 | -42.7 | -56.4 | -56.2 | -42.6 | -36.0 | -43.2 | -50.9 | -48.7 |
| Receivables turnover | 7.27 | 7.17 | 6.71 | 7.12 | 7.27 | 7.03 | 7.41 | 7.16 | 7.08 | 7.12 |
| Payables turnover | 2.40 | 2.55 | 2.45 | 2.28 | 2.32 | 2.53 | 2.80 | 2.63 | 2.51 | 2.56 |
| Inventory turnover | 7.32 | 7.25 | 7.04 | 6.93 | 7.18 | 7.35 | 8.12 | 8.22 | 8.45 | 8.54 |
| Asset turnover | 1.14 | 1.11 | 1.04 | 1.01 | 0.95 | 0.92 | 0.99 | 0.98 | 0.99 | 0.98 |
| Average receivables | $2.39B | $2.21B | $2.13B | $1.88B | $1.74B | $1.64B | $1.54B | $1.51B | $1.47B | $1.37B |
| Average payables | $691.1M | $623.0M | $625.3M | $647.8M | $614.7M | $508.7M | $446.3M | $443.8M | $440.8M | $403.0M |
| Average inventory | $226.5M | $219.0M | $217.8M | $212.7M | $198.6M | $175.2M | $154.0M | $142.2M | $130.8M | $120.7M |
| Intangibles / total assets | 25.5% | 27.7% | 28.7% | 29.6% | 30.9% | 29.4% | 33.9% | 34.3% | 37.6% | 38.9% |
Computed from UHS's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
UHS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Universal Health traded at 9.4 times earnings, against a 10-year median of 14.3. Based on the latest twelve months, the trailing P/E is 7.6 and the forward P/E is 7.3. Universal Health earned a return on equity of 21.4% and a return on invested capital of 12.7% in fiscal 2025. It ended the year with $5.5 billion of debt and $137.8 million in cash and short-term investments, net debt of $5.4 billion. It returned $1.0 billion to shareholders: $51.3 million in dividends and $968.0 million in share buybacks, 120% of free cash flow. The share count fell 34.5% from 98.4M to 64.5M over 9 years.
See the UHS income statement, the UHS chart for price history, or the UHS stock overview for the latest quote and news.
UHS key metrics FAQ
What is Universal Health's P/E ratio?
Universal Health's trailing P/E ratio is 7.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 7.3. At the end of fiscal 2025 it was 9.4, compared with a 10-year median of 14.3.
What is Universal Health's EV/EBITDA?
Universal Health's enterprise value was 7.1 times EBITDA at the end of fiscal 2025 (enterprise value $19.4 billion, EBITDA $2.7 billion); the current EV/EBITDA is 5.6.
What is Universal Health's return on equity?
Universal Health's return on equity (ROE) was 21.4% in fiscal 2025: net income of $1.5 billion on average shareholders' equity of $7.0 billion.
What is Universal Health's ROIC?
Universal Health's return on invested capital was 12.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Universal Health have?
Universal Health had total debt of $5.5 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.76 and $5.4 billion of net debt (1.96 times EBITDA).
What is Universal Health's dividend yield?
Universal Health's forward dividend yield is 0.38%. Universal Health paid $51.3 million in dividends in fiscal 2025 ($0.80 per share), a payout ratio of 3.4%.
Does Universal Health buy back its shares?
Yes. Universal Health spent $968.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −5.1% over the year, to 64.5M..
What is Universal Health's free cash flow yield?
Universal Health generated $849.2 million of free cash flow in fiscal 2025, a free cash flow yield of 6.0% on its market value at year-end ($14.1 billion).
What is Universal Health's current ratio?
Universal Health's current ratio was 1.05 at the end of fiscal 2025: current assets were 1.05 times current liabilities.